1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Motherisk Update 2014
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting,
Details to be announced
- Read more in our News Archive
Current Studies at Motherisk
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Are probiotics safe for use during pregnancy and lactation?
Jackie Elias, RPh, Pina Bozzo and Adrienne Einarson, RN
There has been a great deal of discussion in both the medical and lay literature about the use of probiotics to improve general health. Subsequently, pregnant women have been asking me if probiotics used for treating conditions such as bacterial vaginosis and diarrhea are safe to use during pregnancy and lactation.
Current data suggest that probiotic supplementation is rarely systemically absorbed when used by healthy individuals. One meta-analysis and several randomized controlled trials conducted with women during the third trimester of pregnancy did not report an increase in adverse fetal outcomes. There have been no published studies addressing Saccharomyces species use in pregnancy. Probiotics are unlikely to be transferred into breast milk.
On a beaucoup parlé, dans les ouvrages médicaux et les médias populaires, de lutilisation des probiotiques pour améliorer létat de santé général. Depuis, des femmes enceintes me demandent si les probiotiques utilisés pour traiter des problèmes comme la vaginose bactérienne et la diarrhée sont sécuritaires durant la grossesse et lallaitement.
Selon les données actuelles, les suppléments de probiotiques sont rarement absorbés systémiquement quand ils sont utilisés par des personnes en santé. Une méta-analyse et quelques études randomisées contrôlées réalisées auprès de femmes durant le troisième trimestre de la grossesse nont pas relevé daugmentation de résultats indésirables pour le fœtus. Aucune étude portant sur lutilisation des suppléments de Saccharomyces durant la grossesse na encore été publiée. Il est peu probable que les probiotiques passent dans le lait maternel.
Probiotics are live microorganisms (in most cases bacteria) that are similar to beneficial microorganisms found naturally in the human gut. They are available to consumers mainly in the form of dietary supplements and foods, and "when administered in adequate amounts confer a health benefit on the host." 1 The most widely used probiotics in Canada are live bacteria such as Lactobacillus and Bifidobacterium species and nonpathogenic yeast such as Saccharomyces. They are available alone or in combination as tablets, drops, liquids, and oral or vaginal capsules; they are also contained in various fermented foods, most commonly yogurt. Probiotics have been used for the treatment of acute diarrhea, antibiotic-associated diarrhea, Clostridium difficile, and yeast and bacterial vaginosis. In healthy humans, lactobacilli are normally present in the oral cavity, ileum, colon, and vagina.
When ingested orally or used vaginally, probiotics are generally considered safe and are well tolerated. One theoretical concern associated with probiotics is the potential for these organisms to cause systemic infections. Although rare, probiotic-related bacteremia and fungemia have been reported. 2 It is estimated that the risk of developing bacteremia from ingested Lactobacillus probiotics is less than 1 per 1 million users, 3 and the risk of developing fungemia from Saccharomyces boulardii is estimated at 1 per 5.6 million users, and is estimated to be lower in healthy individuals. 4 There have been no reports of bifidobacterium sepsis associated with the use of probiotics in healthy individuals. 5 Risk factors for systemic infections include immunosuppression, critical illness, central venous catheters, and impairment of the intestinal epithelial barrier. 3 Probiotics administered orally to combat urogenital infections are not systemically absorbed but rather get to the site of action by passage through the gastrointestinal system and ascending into the vagina. 6
Use in pregnancy
Because the risk of probiotic-induced bacteremia and fungemia is low, probiotics are unlikely to reach the systemic circulation of the fetus, and therefore are unlikely to cause harm. A meta-analysis and systematic review of 8 randomized control trials of probiotic use in more than 1500 pregnant women was published. 7 Most of the women began probiotic treatment between 32 and 36 weeks gestation and continued until delivery. The studies included in the meta-analysis compared Lactobacillus spp alone or in combination with Bifidobacterium spp with placebo. There was no increase in the incidence of miscarriages or malformations, which was expected because probiotic use mostly occurred in the third trimester and was therefore unlikely to affect organogenesis. There was no significant difference in birth weight, gestational age, or the incidence of cesarean section.
Several randomized control trials conducted in pregnant women in the third trimester of pregnancy were published following the meta-analysis ( Table 1). 8– 15 These studies examined Lactobacillus spp and Bifidobacterium spp as monotherapy or in combination. Although not designed to directly evaluate pregnancy outcomes, these studies did not suggest an increase in adverse outcomes related to probiotics. Two observational studies examining the use of lactobacilli in the first trimester of pregnancy reported no increased risk of malformations. 16, 17
Table 1. Randomized placebo-control trials of probiotics exposure during pregnancy
|Study||No. of patients||Period of exposure||Probiotics||Pregnancy outcomes||Comments|
|Boyle et al,8 2008||73||36 weeks gestation to delivery||Lactobacillus rhamnosus GG||Not reported||None|
|Kopp et al,9 2008||68||4–6 weeks before expected delivery to 6 months after delivery||L rhamnosus GG||No significant difference in gestational age, birth weight, or method of delivery||Selected women with uneventful pregnancies and without underlying chronic disease (ie, diabetes mellitus, rheumatoid arthritis, chronic infectious disease)|
|Kukkonen et al,10 2008||1223||4 weeks before expected delivery||L rhamnosus GG and LC705; Bifidobacterium breve Bb99; and Propionibacterium freudenreichii ssp shermanii JS||No significant difference in birth weight, birth length, and incidence of vaginal delivery||Excluded birth at < 37 weeks gestation and infants born with major malformations. Babies also received treatment for 6 months after delivery|
|Huurre et al,11 2008||140||First trimester to end of exclusive breastfeeding||L rhamnosus GG and Bifidobacterium lactis Bb12||No significant difference in gestational age or incidence of cesarean section||Women with chronic or metabolic disease before or during early pregnancy were excluded|
|Kuitunen et al,12 2009||1223||36 weeks gestation to delivery||L rhamnosus LC705, B breve Bb99, and P freudenreichii ssp shermanii JS||No significant difference in birth weight||Babies received treatment for 6 months after delivery|
|Niers et al,13 2009||156||6 weeks before expected delivery to delivery||Bifidobacterium bifidum W23 and B lactis W52||No significant difference in the incidence of cesarean section, birth weight, or prematurity or gestational age||Babies received treatment for 12 months after delivery|
|Allen et al,14 2010||454||36 weeks gestation to delivery||Lactobacillus salivarius CUL61 and Lactobacillus paracasei CUL08||No significant difference in adverse events related to pregnancy or childbirth||Babies received treatment for 6 months after delivery|
|Luoto et al,15 2010,||256||First trimester to end of exclusive breastfeeding||L rhamnosus GG and B lactis Bb12||No significant differences in incidence of adverse outcomes; significantly lower birth weight (P = .035) and shorter birth length(P = .028)||None|
There are 2 published randomized control trials 11, 15 of women exposed to probiotics commencing in the first trimester until the end of exclusive breastfeeding ( Table 1). 8– 15 Both studies examined the combination of Lactobacillus rhamnosus strain GG and Bifidobacterium lactis compared with placebo. Neither study was specifically designed to examine pregnancy outcomes; therefore, malformations were not reported. Luoto et al 15 found that infants born to women in the probiotics group had statistically significant lower risk of increased birth weight (P = .035) and birth length (P = .028); however, the clinical significance of this slight difference is unknown. This finding was not confirmed in the study by Huurre et al. 11 Both studies demonstrated no significant difference in gestational age or the incidence of cesarean section. There have been no published studies addressing Saccharomyces spp as an intervention for pregnant women.
Use in breastfeeding
Because probiotics are rarely systemically absorbed, they are not expected to transfer into breast milk. One randomized control trial examined Lactobacillus reuteri levels in 174 colostrum samples after maternal and infant oral supplementation of this probiotic. 18 Although higher in the active than in the placebo group, the prevalence of L reuteri in colostrum was low and not clinically important. Abrahamsson et al 18 suggested that the most likely origin of L reuteri in colostrum was external contamination from the gastrointestinal tract. There are no published data regarding adverse effects in breastfed infants. In several of the studies previously mentioned, 10, 12– 14 infants received probiotic therapy after delivery without an increase in adverse effects.
Probiotics do not appear to pose any safety concerns for pregnant and lactating women. Systemic absorption is rare when probiotics are used by healthy individuals, and the current literature does not indicate an increase in adverse pregnancy outcomes.
Motherisk questions are prepared by the Motherisk Team at The Hospital for Sick Children in Toronto, Ont. Ms. Elias is a doctoral candidate in the Faculty of Pharmacy at the University of Toronto. At the time this paper was written, Ms. Bozzo was a member and Ms. Einarson was Assistant Director of the Motherisk Program. Ms. Bozzo is now Assissant Director and Ms. Einarson continues to be a member of the Motherisk Program.
Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.
Published Motherisk Updates are also available on the Canadian Family Physician website ( www.cfp.ca).
Canadian Family Physician
March 2011 vol. 57 no. 3 299-301
Copyright © 2011 by The College of Family Physicians of Canada
- Food and Agriculture Organization of the United Nations, World Health Organization. Guidelines for the evaluation of probiotics in food. London, ON: Food and Agriculture Organization of the United Nations and World Health Organization; 2002. Available from: www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 2010 Oct 28.
- Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl_2):S104–11.
[Abstract/Free Full Text]
- Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36(6):775–80. Epub 2003 Mar 5.
[Abstract/Free Full Text]
- Karpa KD. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother 2007;41(7):1284–7. Epub 2007 Jun 26.
[Abstract/Free Full Text]
- Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83(6):1256–64.
[Abstract/Free Full Text]
- Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001;30(1):49–52. [Medline]
- Dugoua JJ, Machado M, Zhu X, Chen X, Koren G, Einarson TR. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can 2009;31(6):542–52. [Medline]
- Boyle RJ, Mah LJ, Chen A, Kivivuori S, Robins-Browne RM, Tang ML. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin Exp Allergy 2008;38(12):1882–90. Epub 2008 Sep 24. [Medline]
- Kopp MV, Goldstein M, Dietschek A, Sofke J, Heinzmann A, Urbanek R. Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-gamma release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates. Clin Exp Allergy 2008;38(4):602–10. Epub 2007 Dec 20. [Medline]
- Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008;122(1):8–12.
[Abstract/Free Full Text]
- Huurre A, Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin Exp Allergy 2008;38(8):1342–8. Epub 2008 May 8. [Medline]
- Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol 2009;123(2):335–41. Epub 2009 Jan 8. [Medline]
- Niers L, Martín R, Rijkers G, Sengers F, Timmerman H, van Uden N, et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 2009;64(9):1349–58. Epub 2009 Apr 9. [Medline]
- Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor M, Garaiova I, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr 2010;140(3):483–8. Epub 2010 Jan 20.
[Abstract/Free Full Text]
- Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr 2010;103(12):1792–9. Epub 2010 Feb 4. [Medline]
- Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA 1981;246(4):343–6.
[Abstract/Free Full Text]
- Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985;65(4):451–5. [Medline]
- Abrahamsson TR, Sinkiewicz G, Jakobsson T, Fredrikson M, Björkstén B. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. J Pediatr Gastroenterol Nutr 2009;49(3):349–54. [Medline]